2,098 Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by PBU The Pension Fund of Early Childhood & Youth Educators

PBU The Pension Fund of Early Childhood & Youth Educators cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.9% in the third quarter, Holdings Channel.com reports. The institutional investor owned 15,584 shares of the biopharmaceutical company’s stock after selling 2,098 shares during the quarter. PBU The Pension Fund of Early Childhood & Youth Educators’ holdings in Regeneron Pharmaceuticals were worth $11,817,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Western Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth $26,000. Armstrong Advisory Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 466.7% in the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 28 shares during the period. Mowery & Schoenfeld Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth $29,000. Trust Co. of Vermont purchased a new stake in Regeneron Pharmaceuticals during the second quarter valued at $29,000. Finally, Fiduciary Financial Advisors purchased a new stake in Regeneron Pharmaceuticals during the second quarter valued at $29,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 0.9%

NASDAQ:REGN opened at $951.19 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $591.52 and a one year high of $991.73. The business has a fifty day moving average price of $813.93 and a 200-day moving average price of $746.44. The firm has a market capitalization of $98.40 billion, a price-to-earnings ratio of 21.00, a price-to-earnings-growth ratio of 1.27 and a beta of 0.10. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 2.89.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. During the same period in the previous year, the business earned $11.83 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 36.3% compared to the same quarter last year. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be paid a $0.94 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.30%.

Insider Transactions at Regeneron Pharmaceuticals

In other news, insider Andrew Murphy sold 4,147 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the transaction, the insider directly owned 47,833 shares of the company’s stock, valued at $36,960,559.10. The trade was a 7.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $1,032,750.00. Following the transaction, the executive vice president owned 13,134 shares of the company’s stock, valued at approximately $11,163,900. This trade represents a 8.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 27,028 shares of company stock valued at $25,025,950. Company insiders own 6.97% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on REGN shares. Bank of America increased their target price on Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday, November 2nd. The Goldman Sachs Group upped their price target on shares of Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the company a “buy” rating in a research report on Friday, July 31st. UBS Group raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price target for the company from $660.00 to $978.00 in a research report on Thursday, October 15th. Leerink Partners increased their price objective on shares of Regeneron Pharmaceuticals from $835.00 to $997.00 and gave the stock a “market perform” rating in a research note on Monday, November 2nd. Finally, BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $898.97.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.